{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:19:19Z","timestamp":1787667559422,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40271-026-00818-1","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:14:53Z","timestamp":1777889693000},"page":"741-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Preferences in Adult Patients with Type 2 and Type 3 Spinal Muscular Atrophy: Evidence from a Discrete Choice Experiment in China"],"prefix":"10.1007","volume":"19","author":[{"given":"Jiaqi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-6220","authenticated-orcid":false,"given":"Shunping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanping","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"9630","key":"818_CR1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333.","journal-title":"Lancet"},{"issue":"1","key":"818_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"8","key":"818_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979\u201384.","journal-title":"Arch Neurol"},{"issue":"23","key":"818_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17238989","volume":"17","author":"I Aranda-Reneo","year":"2020","unstructured":"Aranda-Reneo I, Pe\u00f1a-Longobardo LM, Oliva-Moreno J, Litzkendorf S, Durand-Zaleski I, Tizzano EF, et al. The burden of spinal muscular atrophy on informal caregivers. Int J Environ Res Public Health. 2020;17(23):8989.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"818_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"818_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3389\/fgene.2019.01255","volume":"17","author":"Y Lin","year":"2019","unstructured":"Lin Y, Lin CH, Yin X, Zhu L, Yang J, Shen Y, et al. Newborn screening for spinal muscular atrophy in China using DNA mass spectrometry. Front Genet. 2019;17(10):1255.","journal-title":"Front Genet"},{"issue":"5","key":"818_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018975","volume":"99","author":"C Li","year":"2020","unstructured":"Li C, Geng Y, Zhu X, Zhang L, Hong Z, Guo X, et al. The prevalence of spinal muscular atrophy carrier in China: evidences from epidemiological surveys. Medicine. 2020;99(5):e18975.","journal-title":"Medicine"},{"issue":"5","key":"818_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, Klouvi L, Mejat A, Ouillade MC, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31(5):419\u201330.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"818_CR9","first-page":"33","volume":"41","author":"T Zhou","year":"2022","unstructured":"Zhou T, Pan J. Affordability of rare disease medications under different coverage levels: a case study of spinal muscular atrophy (in Chinese). Zhongguo Wei Sheng Jing Ji. 2022;41(2):33\u20138.","journal-title":"Zhongguo Wei Sheng Jing Ji"},{"issue":"1","key":"818_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):1\u201316.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"818_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u201352.","journal-title":"Lancet Neurol"},{"issue":"7","key":"818_CR12","doi-asserted-by":"publisher","first-page":"7S23","DOI":"10.1016\/S0929-693X(20)30273-6","volume":"27","author":"E Salort-Campana","year":"2020","unstructured":"Salort-Campana E, Quijano-Roy S. Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg\u2013Welander disease). Arch Pediatr. 2020;27(7):7S23-8.","journal-title":"Arch Pediatr"},{"issue":"8","key":"818_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946\u201351.","journal-title":"J Child Neurol"},{"issue":"16","key":"818_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168962","volume":"22","author":"LC Chong","year":"2021","unstructured":"Chong LC, Gandhi G, Lee JM, Yeo WWY, Choi SB. Drug discovery of spinal muscular atrophy (SMA) from the computational perspective: a comprehensive review. Int J Mol Sci. 2021;22(16):8962.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"818_CR15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"15","key":"818_CR16","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"issue":"3","key":"818_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","volume":"21","author":"S Ramdas","year":"2020","unstructured":"Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307\u201315.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"818_CR18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","volume":"40","author":"D Fox","year":"2022","unstructured":"Fox D, To TM, Seetasith A, Patel AM, Iannaccone ST. Adherence and persistence to nusinersen for spinal muscular atrophy: a US claims-based analysis. Adv Ther. 2022;40(3):903.","journal-title":"Adv Ther"},{"issue":"12","key":"818_CR19","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, Patel A, Shi S, Davidson M, et al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38(12):5809\u201328.","journal-title":"Adv Ther"},{"issue":"5","key":"818_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"9","key":"818_CR21","doi-asserted-by":"publisher","DOI":"10.2196\/45747","volume":"26","author":"L Wang","year":"2023","unstructured":"Wang L, Liu S, Jiang S, Li C, Lu L, Fang Y, et al. Quantifying benefit-risk trade-offs toward prophylactic treatment among adult patients with hemophilia A in China: discrete choice experiment study. JMIR Public Health Surveill. 2023;26(9):e45747.","journal-title":"JMIR Public Health Surveill"},{"issue":"6","key":"818_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18320","volume":"6","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhai P, Jiang S, Li C, Li S. Blood donors\u2019 preferences toward incentives for donation in China. JAMA Netw Open. 2023;6(6):e2318320.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"818_CR23","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41436-020-0927-x","volume":"22","author":"S Jiang","year":"2020","unstructured":"Jiang S, Anis AH, Cromwell I, Mohammadi T, Schrader KA, Lucas J, et al. Health-care practitioners\u2019 preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment. Genet Med. 2020;22(12):2011\u20139.","journal-title":"Genet Med"},{"issue":"1","key":"818_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S. Patient preferences in targeted pharmacotherapy for cancers: a systematic review of discrete choice experiments. Pharmacoeconomics. 2023;41(1):43\u201357.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"818_CR25","first-page":"593","volume":"16","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhai P, Zhang Y, Jiang S, Chen G, Li S. Gauging Incentive Values and Expectations (G.I.V.E.) among blood donors for nonmonetary incentives: developing a preference elicitation instrument through qualitative approaches in Shandong, China. Patient Auckland N Z. 2023;16(6):593\u2013606.","journal-title":"Patient Auckland N Z"},{"issue":"S1","key":"818_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40273-021-01118-2","volume":"40","author":"SH Lo","year":"2022","unstructured":"Lo SH, Lawrence C, Mart\u00ed Y, Caf\u00e9 A, Lloyd AJ. Patient and caregiver treatment preferences in type 2 and non-ambulatory type 3 spinal muscular atrophy: a discrete choice experiment survey in five European countries. Pharmacoeconomics. 2022;40(S1):103\u201315.","journal-title":"Pharmacoeconomics"},{"issue":"S1","key":"818_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40273-021-01092-9","volume":"40","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gorni K, Sutherland CS, Mart\u00ed Y, Lloyd A, Paracha N. Preferences and utilities for treatment attributes in type 2 and non-ambulatory type 3 spinal muscular atrophy in the United Kingdom. Pharmacoeconomics. 2022;40(S1):91\u2013102.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"818_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16(1):36.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"818_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/dmcn.15135","volume":"64","author":"KA Carey","year":"2022","unstructured":"Carey KA, Farrar MA, Kasparian NA, Street DJ, De Abreu Lourenco R. Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment. Dev Med Child Neurol. 2022;64(6):753\u201361.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"818_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737167.2017.1389648","volume":"17","author":"EM Janssen","year":"2017","unstructured":"Janssen EM, Marshall DA, Hauber AB, Bridges JFP. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):531\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"818_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40271-020-00416-9","volume":"13","author":"SL Lim","year":"2020","unstructured":"Lim SL, Yang JC, Ehrisman J, Havrilesky LJ, Reed SD. Are videos or text better for describing attributes in stated-preference surveys? Patient. 2020;13(4):401\u20138.","journal-title":"Patient"},{"issue":"5","key":"818_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient Auckl. 2015;8(5):373\u201384.","journal-title":"Patient Auckl"},{"issue":"63","key":"818_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chieco.2020.101538","volume":"1","author":"S Jiang","year":"2020","unstructured":"Jiang S, Gu Y, Yang F, Wu T, Wang H, Cutler H, et al. Tertiary hospitals or community clinics? An enquiry into the factors affecting patients\u2019 choice for healthcare facilities in urban China. China Econ Rev. 2020;1(63):101538.","journal-title":"China Econ Rev"},{"key":"818_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1050407","volume":"11","author":"H Ma","year":"2023","unstructured":"Ma H, Jia E, Ma H, Pan Y, Jiang S, Xiong J. Preferences for public long-term care insurance among middle-aged and elderly residents: a discrete choice experiment in Hubei Province, China. Front Public Health. 2023;11:1050407.","journal-title":"Front Public Health"},{"issue":"3","key":"818_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1536867X0700700306","volume":"7","author":"AR Hole","year":"2007","unstructured":"Hole AR. Fitting mixed logit models by using maximum simulated likelihood. Stata J. 2007;7(3):388\u2013401.","journal-title":"Stata J"},{"key":"818_CR36","volume-title":"Discrete choice methods with simulation","author":"KE Train","year":"2009","unstructured":"Train KE. Discrete choice methods with simulation. Cambridge: Cambridge University Press; 2009."},{"key":"818_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jocm.2016.09.005","volume":"21","author":"A Daly","year":"2016","unstructured":"Daly A, Dekker T, Hess S. Dummy coding vs effects coding for categorical variables: clarifications and extensions. J Choice Model. 2016;21:36\u201341.","journal-title":"J Choice Model"},{"key":"818_CR38","unstructured":"Vaughan L, Bardsley M, Bell D, Davies M, Goddard A, Imison C, et al. Models of generalist and specialist care in smaller hospitals in England: a mixed-methods study [Internet]. Southampton (UK): NIHR Journals Library; 2021. (Health Services and Delivery Research). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568036\/.  Accessed 20 Nov 2023."},{"issue":"4","key":"818_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/JND-200611","volume":"8","author":"MC Walter","year":"2021","unstructured":"Walter MC, Chiriboga C, Duong T, Goemans N, Mayhew A, Ouillade L, et al. Improving care and empowering adults living with SMA: a call to action in the new treatment era. J Neuromuscul Dis. 2021;8(4):543\u201351.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"818_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","volume":"15","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey. Orphanet J Rare Dis. 2020;15(1):217.","journal-title":"Orphanet J Rare Dis"},{"key":"818_CR41","unstructured":"MDA_OneVoice_Whitepaper.pdf [Internet]. https:\/\/www.mda.org\/sites\/default\/files\/2018\/12\/MDA_OneVoice_Whitepaper.pdf. Accessed 26 Nov 2023."},{"issue":"5","key":"818_CR42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/mus.27519","volume":"65","author":"N Rad","year":"2022","unstructured":"Rad N, Cai H, Weiss MD. Management of spinal muscular atrophy in the adult population. Muscle Nerve. 2022;65(5):498\u2013507.","journal-title":"Muscle Nerve"},{"issue":"5","key":"818_CR43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.clinthera.2019.03.012","volume":"41","author":"R Cruz","year":"2019","unstructured":"Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating benefit-risk decision-making in spinal muscular atrophy: a first-ever study to assess risk tolerance in the SMA patient community. Clin Ther. 2019;41(5):943-960.e4.","journal-title":"Clin Ther"},{"issue":"3","key":"818_CR44","first-page":"194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK. Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24(3):194\u2013203.","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00818-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00818-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00818-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:26:31Z","timestamp":1787664391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00818-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00818-1","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SL, LD, and LL conceptualized the rationale and design of the study. Data collection was supervised by HX and DL. JY wrote the original manuscript and performed data analysis. SJ provided methodological guidance and contributed to manuscript editing and refinement. All authors participated in revisions of earlier manuscript drafts and approved the final manuscript.","order":1,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients and\/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.","order":3,"name":"Ethics","label":"Patient and public involvement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants agreed that their anonymized data could be used exclusively for academic publication.","order":4,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the Center for Health Management and Policy Research, Shandong University (ECSHCMSDU20230403).","order":5,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are available on reasonable request.","order":6,"name":"Ethics","label":"Availability of data and materials","group":{"name":"EthicsHeading","label":"Declarations"}}]}}